Ionis Pharmaceuticals (NASDAQ:IONS) EVP Holly Kordasiewicz Sells 4,141 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Holly Kordasiewicz sold 4,141 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $75.66, for a total value of $313,308.06. Following the sale, the executive vice president directly owned 14,718 shares of the company’s stock, valued at $1,113,563.88. This represents a 21.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Ionis Pharmaceuticals Stock Performance

Shares of Ionis Pharmaceuticals stock opened at $77.53 on Wednesday. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. The stock’s fifty day moving average is $78.90 and its two-hundred day moving average is $64.33. Ionis Pharmaceuticals, Inc. has a 52 week low of $23.95 and a 52 week high of $86.15. The company has a market capitalization of $12.56 billion, a PE ratio of -45.88 and a beta of 0.28.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.35. The firm had revenue of $156.72 million during the quarter, compared to analyst estimates of $131.75 million. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. The business’s revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.95) earnings per share. As a group, analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in IONS. Steigerwald Gordon & Koch Inc. purchased a new position in Ionis Pharmaceuticals in the third quarter valued at about $25,000. Golden State Wealth Management LLC boosted its holdings in shares of Ionis Pharmaceuticals by 198.4% in the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock valued at $25,000 after buying an additional 250 shares in the last quarter. Mather Group LLC. purchased a new position in shares of Ionis Pharmaceuticals in the 3rd quarter worth approximately $27,000. Allworth Financial LP grew its position in shares of Ionis Pharmaceuticals by 231.8% in the 2nd quarter. Allworth Financial LP now owns 740 shares of the company’s stock worth $29,000 after buying an additional 517 shares during the last quarter. Finally, Quarry LP bought a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $38,000. Institutional investors own 93.86% of the company’s stock.

Trending Headlines about Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Analyst / media bullishness on olezarsen: A recent Seeking Alpha piece highlights an expected 2026 launch of olezarsen in SHTG and argues that approval/commercial rollout could drive a substantial revenue inflection for Ionis; the article notes strong recent momentum and positions olezarsen as the key upside catalyst. Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
• Neutral Sentiment: Trading and technicals: Intraday volume is elevated (~4.9M shares vs. a ~1.5M average), suggesting the market is actively reacting to the news flow; the stock is above its 200‑day moving average (support) but near the 50‑day average—momentum could depend on upcoming clinical/commercial milestones.
• Negative Sentiment: Large, concentrated insider selling: Multiple executives (including CEO Brett P. Monia and several EVPs) sold shares on Jan 16 totaling roughly 117K shares (~$8.8M) — CEO sale (~44K shares, ~$3.3M) and several EVP sales of ~8–13K shares each. These filings can be reviewed in the SEC disclosures, which may signal tax/diversification activity but can also weigh on sentiment.
  Bennett filing
  Birchler filing
  Devers filing
  Hougen filing
  Jenne filing
  Kordasiewicz filing
  Monia (CEO) filing
  O’neil filing
  Schneider filing
  Swayze filings

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Barclays lifted their price target on shares of Ionis Pharmaceuticals from $80.00 to $95.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Cowen reaffirmed a “buy” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, December 3rd. Oppenheimer upped their target price on Ionis Pharmaceuticals from $84.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, October 8th. Guggenheim increased their price target on Ionis Pharmaceuticals from $90.00 to $92.00 and gave the stock a “buy” rating in a research report on Tuesday, September 23rd. Finally, Stifel Nicolaus lifted their price objective on Ionis Pharmaceuticals from $43.00 to $67.00 and gave the company a “hold” rating in a report on Monday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $87.05.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.